{"id":50075,"date":"2021-03-15T14:02:42","date_gmt":"2021-03-15T18:02:42","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=50075"},"modified":"2023-06-06T18:07:25","modified_gmt":"2023-06-06T22:07:25","slug":"clinicians-may-underreport-adverse-events-phase-1-trials","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/","title":{"rendered":"Clinicians May Underreport Adverse Events in Phase 1 Trials"},"content":{"rendered":"
\"Ethan
Ethan Basch, MD, MSc<\/figcaption><\/figure>\n

Patient-clinician agreement for symptomatic adverse events in phase 1 trials appeared moderate to poor, suggesting clinicians are underreporting toxicity, according to a study published in the Journal of the National Cancer Institute<\/em><\/a>.<\/p>\n

Ethan\u00a0Basch<\/a>, MD, MSc, the Richard M. Goldberg Distinguished Professor of Medical Oncology and director of the UNC Cancer Outcomes and Research Program at UNC Lineberger Comprehensive Cancer Center, wrote an editorial accompanying the study<\/a>, with Christina Yap, PhD, professor of clinical trials biostatistics at The Institute of Cancer Research in the UK.<\/p>\n

“This study represents a \u201cmeaningful contribution\u201d to understanding the use of patient-reported outcomes in phase 1 trials,” wrote Basch and Yap. However, they recognized the need for clarity in how such information should best be used in early-phase trials.<\/p>\n

\u201cTo achieve patient-centered drug development, methods are needed for integrating patient-reported outcomes into early-phase trials. Substantial strides have been made in this direction. Patients are the ultimate recipients of drugs, so their perspectives are essential to determining tolerability.\u201d<\/p>\n

Read more in Healio<\/a>.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Patient-clinician agreement for symptomatic adverse events in phase 1 trials appeared moderate to poor, suggesting clinicians are underreporting toxicity, according to a study published in the Journal of the National Cancer Institute. Ethan\u00a0Basch, MD, MSc, the Richard M. Goldberg Distinguished Professor of Medical Oncology and director of the UNC Cancer Outcomes and Research Program at … Read more<\/a><\/p>\n","protected":false},"author":69419,"featured_media":4117,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,517],"tags":[630],"class_list":["post-50075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-oncology","tag-630","odd"],"acf":[],"yoast_head":"\nClinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"Patient-clinician agreement for symptomatic adverse events in phase 1 trials appeared moderate to poor, suggesting clinicians are underreporting toxicity, according to a study published in the Journal of the National Cancer Institute. Ethan\u00a0Basch, MD, MSc, the Richard M. Goldberg Distinguished Professor of Medical Oncology and director of the UNC Cancer Outcomes and Research Program at … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T18:02:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T22:07:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Morris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Morris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\"},\"author\":{\"name\":\"Kim Morris\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"headline\":\"Clinicians May Underreport Adverse Events in Phase 1 Trials\",\"datePublished\":\"2021-03-15T18:02:42+00:00\",\"dateModified\":\"2023-06-06T22:07:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\"},\"wordCount\":184,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg\",\"keywords\":[\"2021\"],\"articleSection\":[\"News\",\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\",\"name\":\"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg\",\"datePublished\":\"2021-03-15T18:02:42+00:00\",\"dateModified\":\"2023-06-06T22:07:25+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg\",\"width\":400,\"height\":500,\"caption\":\"Ethan Basch, MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinicians May Underreport Adverse Events in Phase 1 Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\",\"name\":\"Kim Morris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"caption\":\"Kim Morris\"},\"description\":\"Medicine - Dept of\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/","og_locale":"en_US","og_type":"article","og_title":"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine","og_description":"Patient-clinician agreement for symptomatic adverse events in phase 1 trials appeared moderate to poor, suggesting clinicians are underreporting toxicity, according to a study published in the Journal of the National Cancer Institute. Ethan\u00a0Basch, MD, MSc, the Richard M. Goldberg Distinguished Professor of Medical Oncology and director of the UNC Cancer Outcomes and Research Program at … Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2021-03-15T18:02:42+00:00","article_modified_time":"2023-06-06T22:07:25+00:00","og_image":[{"width":400,"height":500,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","type":"image\/jpeg"}],"author":"Kim Morris","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Kim Morris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/"},"author":{"name":"Kim Morris","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"headline":"Clinicians May Underreport Adverse Events in Phase 1 Trials","datePublished":"2021-03-15T18:02:42+00:00","dateModified":"2023-06-06T22:07:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/"},"wordCount":184,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","keywords":["2021"],"articleSection":["News","Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/","name":"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","datePublished":"2021-03-15T18:02:42+00:00","dateModified":"2023-06-06T22:07:25+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","width":400,"height":500,"caption":"Ethan Basch, MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Clinicians May Underreport Adverse Events in Phase 1 Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529","name":"Kim Morris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","caption":"Kim Morris"},"description":"Medicine - Dept of","url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2-240x300.jpeg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2-150x150.jpeg","featured_image_alt":"Ethan Basch, MD","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"},{"name":"Oncology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/oncology\/"}],"tag_details":[{"name":"2021","link":"https:\/\/www.med.unc.edu\/medicine\/news\/tag\/2021\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/50075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/69419"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=50075"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/50075\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/4117"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=50075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=50075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=50075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}